This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Final Opinion: Digging into the phase 2 TITRATE Clinical trial data on Pfizer's GLP-1 agonist candidate danuglipron (PF-06882961) in patients with type 2 diabetes and obesity

Ticker(s): PFE

Who's the expert?

Institution: Primary Care Associates

  • Community Endocrinologist in rural area. 
  • Treats 750 patients with type 2 Diabetes.
  • Prescribed Mounjaro to twelve patients. 

Interview Goal
A third look: Digging into the phase 2 TITRATE Clinical trial data on Pfizer's GLP-1 agonist candidate danuglipron (PF-06882961) in patients with type 2 diabetes and obesity

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.